Our Pipeline
Our Pipeline
Our programs are first-in-class and internally generated, each representing an opportunity to make a transformational impact across numerous diseases with high unmet need.
Harnessing SIRP Biology to Target Pathogenic Immune Cells
We are advancing a novel portfolio of SIRP-directed therapies designed to selectively target the activated immune cells that drive disease. Our programs are built on a deep understanding of SIRP biology and have the potential to address a broad range of immune-mediated diseases and cancer with significant unmet need.
SIRP: signal regulatory protein; NK: natural killer
Learn how ipsoprubart (ELA026) is designed to address the underlying drivers of sHLH
Learn how ELA822 is designed to selectively deplete activated, disease-driving T cells in immune-mediated diseases
SIRP: signal regulatory protein; NK: natural killer